3034-57-9|2-Amino-5-bromo-4-methylthiazole| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 3034-57-9 ] Purity: 97% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 3034-57-9 ]

CAS No. :	3034-57-9
Formula :	C₄H₅BrN₂S
M.W :	193.06
SMILES Code :	NC1=NC(=C(S1)Br)C
MDL No. :	MFCD09260911
InChI Key :	XZYIDZIGJVUTKE-UHFFFAOYSA-N
Pubchem ID :	12954373

Safety of [ 3034-57-9 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H319
Precautionary Statements:	P305+P351+P338

Computational Chemistry of [ 3034-57-9 ] Show Less

Physicochemical Properties

Num. heavy atoms	8
Num. arom. heavy atoms	5
Fraction Csp3	0.25
Num. rotatable bonds	0
Num. H-bond acceptors	1.0
Num. H-bond donors	1.0
Molar Refractivity	39.18
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	67.15 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	1.56
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	2.03
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	1.8
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	0.67
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	2.58
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	1.73

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-2.78
Solubility	0.322 mg/ml ; 0.00167 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-3.07
Solubility	0.165 mg/ml ; 0.000855 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-2.18
Solubility	1.28 mg/ml ; 0.00664 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-6.04 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	2.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	2.43

Application In Synthesis of [ 3034-57-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 3034-57-9 ]

[ 3034-57-9 ] Synthesis Path-Downstream 1~36

1
[ 1603-91-4 ]
[ 3034-57-9 ]

Yield	Reaction Conditions	Operation in experiment
76%	With bromine; sodium hydrogencarbonate; In chloroform; water;	Step 1: Synthesis of 2-amino-5-bromo-4-methylthiazole A solution of bromine in chloroform, consisting of 66.7 ml (1.30 mol) of Br2 in 1000 ml of CHCl3, is added dropwise to a solution of 120 g (1.05 mol) of 2-amino-4-methylthiazole in 2300 ml of CHCl3, with stirring. A precipitate appears during the addition. Stirring is maintained for 48 h. The reaction medium is then filtered and the hydrobromide is washed with methylene chloride and then with pentane. The hydrobromide is dissolved in 2000 ml of water and then rendered basic by the addition of 850 ml of a 10percent aqueous solution of sodium bicarbonate. This solution is then extracted with methylene chloride. The organic phase is dried over sodium sulfate. A crystalline residue is obtained after removal of the solvent under vacuum. Brown crystals: m=155 g (crude yield: 76percent) M.p.KB =112°-113° C. 1 H NMR (delta ppm, DMSO) 2.05 (s, 3H, CH3); 7.15 (s, 2H, NH2).
	With bromine; In aq. sulfuric acid;	i) 5-Bromo-4-methyl-thiazol-2-ylamine 4-Methyl-thiazol-2-ylamine (4.00 g, 35.0 mmol) was dissolved in 17.5 mL of 20percent aq. sulfuric acid, cooled to 0° C., and treated drop wise with Br2 (1.97 mL, 1.1 eq.). After 10 Min. at 0° C. and 60 Min. at RT, the reaction mixture was carefully poured onto crashed ice/Na2CO3, twofold extracted with AcOEt, washed with water, dried over sodium sulfate, and evaporated to dryness. Thereby, 5.20 g of the title compound was isolated as light brown solid, sufficiently pure to be used for the next step. MS (ISP): 193.1, 195.1 [M+H]+.

References: [1]Patent: US5322846,1994,A .
[2]Chemische Berichte,1939,vol. 72,p. 1470,1474.
[3]Bulletin de la Societe Chimique de France,1954,p. 1048,1052.
[4]Patent: US2457078,1944, .
[5]Chemische Berichte,1939,vol. 72,p. 1470,1474.
[6]Patent: US2009/143448,2009,A1 .

2
[ 3034-57-9 ]
[ 107-03-9 ]
N-(4-methyl-5-propylmercapto-thiazol-2-yl)-acetamide [ No CAS ]

References: [1]Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan,1952,vol. 72,p. 1124,1127.
Chem.Abstr.,1953,p. 6407.

3
[ 3034-57-9 ]
[ 109-79-5 ]
N-(5-butylmercapto-4-methyl-thiazol-2-yl)-acetamide [ No CAS ]

References: [1]Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan,1952,vol. 72,p. 1124,1127.
Chem.Abstr.,1953,p. 6407.

4
[ 3034-57-9 ]
[ 1124-31-8 ]
[ 850852-87-8 ]

References: [1]Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan,1950,vol. 70,p. 305.
Chem.Abstr.,1951,p. 1579.

5
[ 3034-57-9 ]
[ 13113-79-6 ]
4-methyl-5-(4-nitro-phenylsulfanyl)-thiazol-2-ylamine [ No CAS ]

References: [1]Journal of the Chemical Society,1947,p. 110,112.

6
[ 3034-57-9 ]
[ 98-88-4 ]
N-(5-bromo-4-methyl-thiazol-2-yl)-benzamide [ No CAS ]

References: [1]Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences,1956,vol. 242,p. 1036.

7
[ 3034-57-9 ]
[ 17356-08-0 ]
[ 103391-99-7 ]

References: [1]Journal of the Chemical Society,1945,p. 925.

8
[ 3034-57-9 ]
[ 17356-08-0 ]
[ 51176-85-3 ]

References: [1]Bulletin de la Societe Chimique de France,1948,p. 816.
[2]Journal of the American Chemical Society,1950,vol. 72,p. 4230.

9
[ 3034-57-9 ]
[ 106-54-7 ]
[ 54406-10-9 ]

References: [1]Journal of the Chemical Society,1947,p. 110,112.

10
[ 3034-57-9 ]
[ 541-31-1 ]
[ 859466-49-2 ]

References: [1]Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan,1952,vol. 72,p. 1124,1127.
Chem.Abstr.,1953,p. 6407.

11
[ 3034-57-9 ]
[ 121-60-8 ]
[ 103647-79-6 ]

References: [1]Journal of the American Chemical Society,1946,vol. 68,p. 453,457.

12
[ 3034-57-9 ]
[ 51176-85-3 ]

References: [1]Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan,1951,vol. 71,p. 9.
Chem.Abstr.,1951,p. 7111.
[2]Journal of the Chemical Society,1945,p. 925.

13
[ 21478-95-5 ]
[ 3034-57-9 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2016,vol. 26,p. 445 - 453.
[2]Bulletin de la Societe Chimique de France,1954,p. 1048,1052.

14
[ 17356-08-0 ]
[ 598-31-2 ]
[ 3034-57-9 ]

References: [1]Acta Pharmacologica et Toxicologica,1946,vol. 2,p. 371,373.

15
[ 3034-57-9 ]
[ 6320-03-2 ]
[ 17119-33-4 ]